Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Islasertib - Thryv Therapeutics

Next Previous
Drug Profile

Islasertib - Thryv Therapeutics

Alternative Names: LQT-1213

Latest Information Update: 21 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Thryv Therapeutics
  • Class Antiarrhythmics; Cardiovascular therapies; Small molecules
  • Mechanism of Action Serum-glucocorticoid regulated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Long QT syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Long QT syndrome

Most Recent Events

  • 24 Jul 2025 Thryv Therapeutics terminates a phase I/II trial for Long QT syndrome in USA (PO) due to company's advancement in an alternative SGK 1 inhibitor (NCT05906732)
  • 13 May 2025 Efficacy and adverse events data from phase I/II WAVE-1 trial for Long QT syndrome released by Thryv Therapeutics
  • 05 Mar 2025 Thryv Therapeutics plans a phase II trial for Long QT syndrome Type 1 in 2025 (Thryv Therapeutics pipeline, March 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top